Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Company Overview
Assertio Holdings Inc (ASRT) is a specialized pharmaceutical company committed to advancing patient care through a focused portfolio of FDA-approved products. The company operates primarily in the areas of neurology, orphan treatments, and specialty medicines, targeting conditions that demand innovative approaches to symptom management and quality of life improvements. With robust commercial capabilities, Assertio leverages both traditional sales forces and modern non-personal promotion strategies to effectively reach healthcare providers and payor networks.
Core Business and Product Portfolio
At its core, Assertio not only markets but also strategically acquires and licenses approved products that solve unmet medical needs. Among its prominent offerings are products approved for neurological indications, including therapies designed to manage postherpetic neuralgia, acute migraine treatments, and formulations aimed at moderating mild to moderate pain. These products are carefully developed and maintained in compliance with rigorous FDA standards, which underscores the company’s commitment to safety and efficacy.
Innovative Commercial Strategy
The company has built a diversified and resilient business model by integrating multiple marketing channels. Through a dedicated sales force and a streamlined non-personal promotion model, Assertio ensures that its treatments are accessible to clinicians and patients across various market segments. This dual approach not only enhances market penetration but also supports effective payor contracting and trade distribution, helping the company maintain a competitive edge in a sector marked by stringent regulatory and competitive pressures.
Market Position and Differentiation
Assertio’s competitive positioning is anchored in its strategic acquisition of established products and its innovative push into emerging therapeutic areas such as oncology. With assets like Rolvedon, the company has demonstrated adaptability and growth in targeted clinical segments. This asset, among others, reflects a forward-thinking and entrepreneurial spirit, aiming to expand patient access and improve treatment outcomes while navigating a complex pharmaceutical landscape. The company’s unwavering commitment to quality and patient-centric care is evident in its rigorous clinical standards and attention to regulatory compliance.
Operational Excellence and Commercial Capabilities
- Extensive Marketing Infrastructure: A combination of traditional and digital promotion channels tailored to maximize product outreach.
- Robust Distribution Network: Strategic partnerships and agreements with key payors facilitate wide and efficient market access.
- Acquisition and Licensing Strategy: A focused portfolio built through thoughtful acquisitions and licensing of clinically validated products.
Expertise and Industry Insight
Assertio exemplifies deep industry expertise by aligning its operational strategies with current trends in pharmaceutical development and market dynamics. The company uses a data-driven approach to decision-making, ensuring that its commercial strategies, regulatory compliance, and product development efforts are both effective and forward compatible. This level of meticulous operational management builds confidence among stakeholders and positions Assertio as a key player in the specialty pharmaceutical space.
Conclusion
In summary, Assertio Holdings Inc stands out as a commercial pharmaceutical company that harmonizes innovation with proven business models. Its commitment to developing and distributing differentiated, FDA-approved treatments illustrates a balanced approach to addressing both current patient needs and market challenges. The company’s integrated commercial infrastructure and focus on quality make it an informative subject for investors seeking deep insights into a specialized segment of the pharmaceutical industry.
Assertio Holdings, Inc. (Nasdaq: ASRT), a specialty pharmaceutical company, announced that CEO Dan Peisert and CFO Paul Schwichtenberg will conduct investor meetings on February 15, 2023, during the SVB Securities Global Biopharma Conference, which will be held virtually.
Investors can schedule one-on-one meetings by contacting their SVB Securities representative or reaching out to Matt Kreps in Investor Relations at Assertio. The company offers a wide range of branded prescription products, focusing on neurology, hospital, and pain and inflammation sectors, and has expanded through licensing, mergers, and acquisitions.
Assertio Holdings, Inc. (Nasdaq: ASRT) announced a $100,000 educational grant to the LGS Foundation to raise awareness about Lennox-Gastaut Syndrome (LGS) and provide educational resources. Assertio recently acquired exclusive rights to SYMPAZAN® (clobazam) oral film, FDA-approved for treating seizures associated with LGS in patients aged two and older. The company aims to enhance awareness of SYMPAZAN's unique oral film delivery method, which simplifies medication administration for LGS patients. This collaboration signifies Assertio's commitment to improving the lives of those affected by LGS.
Assertio Holdings, Inc. (Nasdaq: ASRT) announced the addition of U.S. Patent No. 11541002 for Sympazan oral film to the FDA's Orange Book, extending patent protection until 2039. This patent is crucial for the treatment of epilepsy with clobazam. The company aims to boost its portfolio through strategic business development, targeting an incremental gross profit increase of $50 million by 2024. Currently, $18 million is secured from recent transactions, including Sympazan. Assertio's focus remains on diversifying its assets and enhancing its market position.
Assertio Holdings announced the grant of restricted stock units (RSUs) and stock options to four newly-hired employees, effective January 3, 2023, totaling 14,804 RSUs and 16,001 options. This initiative, per NASDAQ Listing Rule 5635(c)(4), aims to attract talent. The stock options have an exercise price of $4.17 per share, equal to the company's closing stock price on the grant date, and will vest annually over three years.
Assertio focuses on differentiated pharmaceutical products in neurology, hospital, and pain management.
Assertio Holdings (NASDAQ: ASRT) will conduct one-on-one investor and business development meetings in San Francisco from January 9-11, 2023, coinciding with the annual JP Morgan Healthcare Conference. The meetings aim to discuss investment opportunities and potential partnerships. Interested parties can reach out to Matt Kreps for investor inquiries or Vanessa Fox for business development meetings via the provided contact information. Assertio is focused on expanding its portfolio through acquisitions and licensing of approved products.
Assertio Holdings, Inc. (ASRT) has raised its 2022 full-year net product sales outlook to over $152 million, an increase from the previous forecast of over $141 million. This revision follows strong sales performance in the fourth quarter, with contributions particularly from Indocin and the newly added Sympazan. CEO Dan Peisert noted that net product sales have consistently exceeded expectations throughout the year, driven by better-than-anticipated volume across the product portfolio.
Assertio Holdings, Inc. (Nasdaq: ASRT) reported a 32% increase in net product sales year-over-year for Q3 2022, totaling $34.3 million. Adjusted EBITDA rose 36% to $21.4 million. The company refinanced its debt to lower costs and extend maturity, enhancing financial flexibility. Assertio expects Sympazan to contribute an additional $1 million in sales in Q4. With cash reserves at $64.8 million, the company revised its full-year guidance to anticipate net product sales exceeding $141 million and adjusted EBITDA surpassing $86 million, reflecting positive operational performance.
Assertio Holdings, Inc. (Nasdaq: ASRT) will release its third-quarter 2022 financial results on November 8, 2022, after market close. A live webcast of the earnings call will follow at 4:30 p.m. ET. Investors can access the call via Assertio's investor relations website. The company focuses on specialty pharmaceuticals, utilizing a non-personal promotional model to enhance product differentiation. Assertio emphasizes growth opportunities through integrating new assets and business development initiatives.
Assertio Holdings has acquired an exclusive license for Sympazan (clobazam) oral film from Aquestive Therapeutics for $9.0 million upfront and an additional $6.0 million upon patent allowance, expected in 2023. This transaction aims to enhance Assertio's portfolio and extend patent coverage potentially to 2039. Sympazan, designed for LGS patients, is anticipated to contribute $4.0 - $4.5 million in adjusted EBITDA and $0.05 in adjusted EPS, aligning with Assertio's growth strategy to achieve $40 million in gross profit by 2024.
Assertio Holdings (Nasdaq: ASRT), a specialty pharmaceutical company, announced its participation in investor conferences during October 2022. Key events include the Windy City Roundup 2022 on October 13, 2022, at Swissotel, Chicago, and the LD Micro Main Event XV on October 25, 2022, at Luxe Sunset Boulevard Hotel, Los Angeles. Presentations will occur at 11:00 a.m. CT and 10:30 a.m. PT, respectively. Management will also host one-on-one meetings. For further details, interested parties should contact Investor Relations.
FAQ
What is the current stock price of Assertio Holdings (ASRT)?
What is the market cap of Assertio Holdings (ASRT)?
What is the core business of Assertio Holdings Inc?
How does Assertio generate its revenue?
What are some key products in Assertio's portfolio?
How does the company achieve market access for its products?
What makes Assertio’s business model unique?
How does Assertio position itself against competitors?
What are the key commercial capabilities of Assertio?
Is there evidence of Assertio’s industry expertise?
